Liver MR Image Acquisition for Technologists Using a Hepatobiliary Agent

Viewing Information

Getting Started

To fully participate in this online program you must be registered and logged in. Read all the information presented below. When ready select the "View Program" tab above.

Claiming CE Credits

To receive CE credits, participants must review the program materials in their entirety and complete the online post examination and evaluation with a score of 80% or better.

Program Summary

This On-Demand version of this Expert Forum webinar, attendees heard about liver magnetic resonance image acquisition utilizing a hepatobiliary agent. You will learn more about Eovist (gadoxetate sodium) including details on its properties, applications in liver imaging and important safety information.

Through a case study review, details on how your liver imaging protocols and workflow can be optimized will be discussed

CE Effective Date: June 1, 2023
CE Expiration Date: June 30, 2026

Format: Self Instructional - Audio Visual with Slides
Educational Credits:
One (1) ARRT Category A CE Credit.
One (1) AHRA CRA Credit
Estimated Completion Time: 1 hour

This program has been sponsored by Bayer Healthcare.

Target Audience & Cost

This program is intended for: Radiologic Technologists, Radiology Administrators and related Imaging Professionals.

There is no cost to participate in this program.

Educational Objectives

Upon completion of this CME activity the healthcare provider should be able to:

  1. Describe the key properties and application of Eovist.
  2. Implement protocols to optimize workflow.
  3. Characterize lesions associated with various liver disease through a review of case examples.

Presented by

 Patricia Barnick, BSRT Patricia Barnick, BSRT
Director, Medical Affairs Communications
Bayer HealthCare

Patricia is a registered MRI and CT technologist, who worked in a variety of clinical positions in radiology for almost 30 years prior to coming to Bayer. Her positions ranged from staff technologist to Chief Technologist of an imaging center that had 5 free standing offices as well as supporting a large in-patient facility with a Level 1 trauma center

Patricia is very grateful for having had the opportunity to start in the early days of clinical MRI, where a solid MR physics background was essential. It has been an amazing experience seeing the technology grow to what it is today. She came to Bayer initially as a clinical support specialist for the contrast portfolio. She joined the Bayer Radiology Medical Affairs division in 2012 where she is able to leverage her clinical experience along with her product knowledge to best serve Bayer customers and more importantly, their patients.


Radiologic Technologists:
This course meets all criteria and has been approved by the AHRA, The Association for Medical Imaging Management for One (1) ARRT Category A CE Credit.

Radiology Administrators:
This course meets all CRA renewal credit criteria and has been approved for One (1) continuing education credit in the following CRA domains: Asset Management (AM) and Operations Management (OM).

For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board or other credentialing organization.

Method of Participation/Criteria for Success

CE Credits
To receive CE credits for participating in this CE activity you must successfully complete the online post examination with a passing score of 80% or higher.

Online examinations return an immediate grade report. Upon receiving a passing score click Continue and complete the evaluation form. To view and print your Statement of Credit click the Print/View Certificate button displayed from within your MyAR Archives page.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Join us for an expert forum webinar where attendees will hear about Eovist®, the only gadolinium-based, liver specific MR contrast agent approved in the US; including details on its properties and applications in liver imaging.  Through a case study review, details on how your liver imaging protocols and workflow can be optimized to reduce exam time will be discussed.

Learning Objectives

At the conclusion of this activity, participants will be able to:

  • Describe the key properties and application of Eovist
  • Implement optimized protocols to reduce exam time
  • Identify various liver disease through a review of case examples

Educational Credits

  • ARRT Category A CE Credits
  • AHRA CRA Credits



Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs. Avoid use of GBCAs in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs.

  • The risk of NSF appears highest among patients with:
    • Chronic, severe kidney disease (GFR <30 mL/min/1.73m2), or
    • Acute kidney injury
  • Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (for example, age >60 years, hypertension or diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing.
  • For patients at highest risk for NSF, do not exceed the recommended EOVIST dose and allow a sufficient period of time for elimination of the drug from the body prior to any re-administration.

Contraindication and Important Information about Hypersensitivity Reactions:

Eovist® is contraindicated in patients with history of severe hypersensitivity reactions to Eovist®. Anaphylactic and other hypersensitivity reactions with cardiovascular, respiratory and cutaneous manifestations, ranging from mild to severe, including shock have uncommonly occurred following Eovist® administration. Before Eovist® administration, assess all patients for any history of a reaction to contrast media, bronchial asthma and allergic disorders. These patients may have an increased risk for a hypersensitivity reaction to Eovist®.

Gadolinium Retention:

Gadolinium is retained for months or years in several organs. Linear GBCAs cause more retention than macrocyclic GBCAs. At equivalent doses, retention varies among the linear agents. Retention is lowest and similar among the macrocyclic GBCAs. Consequences of gadolinium retention in the brain have not been established, but they have been established in the skin and other organs in patients with impaired renal function. While clinical consequences of gadolinium retention have not been established in patients with normal renal function, certain patients might be at higher risk. These include patients requiring multiple lifetime doses, pregnant and pediatric patients, and patients with inflammatory conditions. Consider the retention characteristics of the agent and minimize repetitive GBCA studies, when possible.

Acute Kidney Injury:

In patients with chronic renal impairment, acute kidney injury sometimes requiring dialysis has been observed with the use of GBCAs. Do not exceed the recommended dose; the risk of acute kidney injury may increase with higher than recommended doses.

Extravasation and Injection Site Reactions:

Ensure catheter and venous patency before the injection of Eovist®. Extravasation into tissues during Eovist® administration may result in local tissue reactions. Strictly avoid intramuscular administration of Eovist® because it may cause myocyte necrosis and inflammation.

Interference with Laboratory Tests:

Serum iron determination using complexometric methods may result in falsely high or low values for up to 24 hours after the examination with Eovist®.

Interference with Visualization of Liver Lesions:

End-stage renal failure or hepatic failure may impair Eovist® imaging performance. In patients with elevated serum ferritin or serum bilirubin >3 mg/dL, reduced hepatic contrast was observed.

Adverse Reactions:

The most frequent (≥0.5%) adverse reactions associated with Eovist® are nausea (1.1%), headache (1.1%), feeling hot (0.8%), dizziness (0.6%), and back pain (0.6%).


Eovist® (gadoxetate disodium) injection is indicated for intravenous use in magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in patients with known or suspected focal liver disease..

Please see Full Prescribing Information for Eovist®.

Medication Guide